TRVN Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Trevena, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.68 |
| 52 Week High | US$19.23 |
| 52 Week Low | US$1.13 |
| Beta | 1.07 |
| 11 Month Change | -15.58% |
| 3 Month Change | -60.75% |
| 1 Year Change | -87.81% |
| 33 Year Change | -99.62% |
| 5 Year Change | -99.61% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Trevena Q2 2022 Earnings Preview
Aug 10Trevena slides on $2M preferred stock offering
Jul 29Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely
Jul 08
Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?
Mar 19Trevena Offers An Enticing Risk-Reward At These Prices
Dec 14Trevena: Remaining Patient After A Disappointing Q2 Earnings
Aug 17Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder
Jun 16Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles
May 10Trevena Investor Presentation - Slideshow
May 08Trevena (TRVN) Investor Presentation - Slideshow
Nov 16Trevena: Reaffirming A Buy On OLINVYK DEA Scheduling
Nov 09DEA classifies Trevena's oliceridine, distribution to start in November
Oct 30Shareholder Returns
| TRVN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | -87.8% | 16.1% | 31.6% |
Return vs Industry: TRVN underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: TRVN underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| TRVN volatility | |
|---|---|
| TRVN Average Weekly Movement | 30.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TRVN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TRVN's weekly volatility has increased from 18% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 23 | Carrie Bourdow | www.trevena.com |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Trevena, Inc. Fundamentals Summary
| TRVN fundamental statistics | |
|---|---|
| Market cap | US$1.45m |
| Earnings (TTM) | -US$34.04m |
| Revenue (TTM) | US$546.00k |
2.7x
P/S Ratio0.0x
P/E RatioIs TRVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRVN income statement (TTM) | |
|---|---|
| Revenue | US$546.00k |
| Cost of Revenue | US$1.59m |
| Gross Profit | -US$1.04m |
| Other Expenses | US$33.00m |
| Earnings | -US$34.04m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -39.40 |
| Gross Margin | -190.48% |
| Net Profit Margin | -6,233.70% |
| Debt/Equity Ratio | -141.0% |
How did TRVN perform over the long term?
See historical performance and comparison